CVS Health (CVS) Stock Forecast & Price Target

Compare

13,680 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CVS Analyst Ratings

Strong Buy

15 Buy

2 Hold

0 Sell

Based on 17 analysts giving stock ratings to

CVS

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CVS Stock 12 Month Forecast

Average Price Target

$79.94

▲(25.75%Upside)

Based on 17 Wall Street analysts offering 12 month price targets for CVS Health in the last 3 months. The average price target is $79.94 with a high forecast of $95.00 and a low forecast of $71.00. The average price target represents a 25.75% change from the last price of $63.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"42":"$42","69":"$69","96":"$96","55.5":"$55.5","82.5":"$82.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$79.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$71.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[42,55.5,69,82.5,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.6,66.01538461538462,68.43076923076923,70.84615384615384,73.26153846153846,75.67692307692307,78.09230769230768,80.50769230769231,82.92307692307692,85.33846153846153,87.75384615384615,90.16923076923077,92.58461538461538,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.6,64.85692307692308,66.11384615384615,67.37076923076923,68.62769230769231,69.88461538461539,71.14153846153846,72.39846153846153,73.65538461538462,74.91230769230769,76.16923076923077,77.42615384615384,78.68307692307692,{"y":79.94,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.6,64.16923076923077,64.73846153846154,65.3076923076923,65.87692307692308,66.44615384615385,67.01538461538462,67.58461538461539,68.15384615384616,68.72307692307692,69.29230769230769,69.86153846153846,70.43076923076923,{"y":71,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.97,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.58,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.02,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.33,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$95.00

Average Price Target$79.94

Lowest Price Target$71.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$68

Hold

6.97%

Upside

Reiterated

05/29/25

CVS Health shows strong financial performance and positive earnings call sentiment, contributing significantly to the score. The technical analysis indicates bearish momentum, and while the valuation is reasonable, it reflects a balanced risk-reward profile. The company's strategic innovations and partnerships are promising, though challenges in specific segments pose risks.

Sarah JamesCantor Fitzgerald

Cantor Fitzgerald

$71

Buy

11.69%

Upside

Reiterated

06/04/25

Cantor Fitzgerald Sticks to Their Buy Rating for CVS Health (CVS)

Andrew Mok CFABarclays

Barclays

$82→$79

Buy

24.27%

Upside

Reiterated

06/03/25

CVS Health price target lowered to $79 from $82 at BarclaysCVS Health price target lowered to $79 from $82 at Barclays

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$85

Buy

33.71%

Upside

Reiterated

05/28/25

Evercore ISI Remains a Buy on CVS Health (CVS)

Michael ChernyLeerink Partners

Leerink Partners

$83

Buy

30.56%

Upside

Reiterated

05/19/25

Leerink Partners Reaffirms Their Buy Rating on CVS Health (CVS)

David S MacdonaldTruist Financial

Truist Financial

$82→$84

Buy

32.14%

Upside

Reiterated

05/12/25

CVS Health price target raised to $84 from $82 at TruistCVS Health price target raised to $84 from $82 at Truist

Lisa GillJ.P. Morgan

J.P. Morgan

$81→$86

Buy

35.28%

Upside

Reiterated

05/07/25

CVS Health (CVS) PT Raised to $86 at JPMorganJPMorgan analyst Lisa Gill raised the price target on CVS Health (NYSE: CVS) to $86.00 (from $81.00) while maintaining a Overweight rating.

Unknown AnalystAccountability Research

Not Ranked

Accountability Research

$74

Buy

16.41%

Upside

Upgraded

05/06/25

Accountability Research upgrades CVS Health (CVS) to BuyAccountability Research analyst Harshit Gupta upgraded CVS Health (NYSE: CVS) from Hold to Buy with a price target of $74.00.

Steven SilverArgus Research

Argus Research

―

Buy

―

Reiterated

05/05/25

Analysts Conflicted on These Healthcare Names: CVS Health (NYSE: CVS), Herbalife (NYSE: HLF) and Zimmer Biomet Holdings (NYSE: ZBH)

Charles RhyeeTD Cowen

TD Cowen

$90→$95

Buy

49.44%

Upside

Reiterated

05/05/25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Oric Pharmaceuticals (NASDAQ: ORIC) and CVS Health (NYSE: CVS)

Stephen BaxterWells Fargo

Wells Fargo

$76→$84

Buy

32.14%

Upside

Reiterated

05/05/25

CVS Health price target raised to $84 from $76 at Wells FargoCVS Health price target raised to $84 from $76 at Wells Fargo

Ben HendrixRBC Capital

RBC Capital

$74→$81

Buy

27.42%

Upside

Reiterated

05/04/25

RBC Capital Sticks to Their Buy Rating for CVS Health (CVS)

Allen LutzBank of America Securities

Bank of America Securities

$80→$85

Buy

33.71%

Upside

Reiterated

05/02/25

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (NASDAQ: ADPT), CVS Health (NYSE: CVS) and Cytokinetics (NASDAQ: CYTK)

Kevin CaliendoUBS

UBS

$67→$71

Hold

11.69%

Upside

Reiterated

05/02/25

CVS Health price target raised to $71 from $67 at UBSCVS Health price target raised to $71 from $67 at UBS

Erin WrightMorgan Stanley

Morgan Stanley

$68→$80

Buy

25.85%

Upside

Reiterated

04/15/25

CVS Health price target raised to $80 from $68 at Morgan StanleyCVS Health price target raised to $80 from $68 at Morgan Stanley

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$68

Hold

6.97%

Upside

Reiterated

05/29/25

Sarah JamesCantor Fitzgerald

Cantor Fitzgerald

$71

Buy

11.69%

Upside

Reiterated

06/04/25

Cantor Fitzgerald Sticks to Their Buy Rating for CVS Health (CVS)

Andrew Mok CFABarclays

Barclays

$82→$79

Buy

24.27%

Upside

Reiterated

06/03/25

CVS Health price target lowered to $79 from $82 at BarclaysCVS Health price target lowered to $79 from $82 at Barclays

Elizabeth Anderson CFAEvercore ISI

Evercore ISI

$85

Buy

33.71%

Upside

Reiterated

05/28/25

Evercore ISI Remains a Buy on CVS Health (CVS)

Michael ChernyLeerink Partners

Leerink Partners

$83

Buy

30.56%

Upside

Reiterated

05/19/25

Leerink Partners Reaffirms Their Buy Rating on CVS Health (CVS)

David S MacdonaldTruist Financial

Truist Financial

$82→$84

Buy

32.14%

Upside

Reiterated

05/12/25

CVS Health price target raised to $84 from $82 at TruistCVS Health price target raised to $84 from $82 at Truist

Lisa GillJ.P. Morgan

J.P. Morgan

$81→$86

Buy

35.28%

Upside

Reiterated

05/07/25

CVS Health (CVS) PT Raised to $86 at JPMorganJPMorgan analyst Lisa Gill raised the price target on CVS Health (NYSE: CVS) to $86.00 (from $81.00) while maintaining a Overweight rating.

Unknown AnalystAccountability Research

Not Ranked

Accountability Research

$74

Buy

16.41%

Upside

Upgraded

05/06/25

Accountability Research upgrades CVS Health (CVS) to BuyAccountability Research analyst Harshit Gupta upgraded CVS Health (NYSE: CVS) from Hold to Buy with a price target of $74.00.

Steven SilverArgus Research

Argus Research

―

Buy

―

Reiterated

05/05/25

Analysts Conflicted on These Healthcare Names: CVS Health (NYSE: CVS), Herbalife (NYSE: HLF) and Zimmer Biomet Holdings (NYSE: ZBH)

Charles RhyeeTD Cowen

TD Cowen

$90→$95

Buy

49.44%

Upside

Reiterated

05/05/25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (NASDAQ: UTHR), Oric Pharmaceuticals (NASDAQ: ORIC) and CVS Health (NYSE: CVS)

Stephen BaxterWells Fargo

Wells Fargo

$76→$84

Buy

32.14%

Upside

Reiterated

05/05/25

CVS Health price target raised to $84 from $76 at Wells FargoCVS Health price target raised to $84 from $76 at Wells Fargo

Ben HendrixRBC Capital

RBC Capital

$74→$81

Buy

27.42%

Upside

Reiterated

05/04/25

RBC Capital Sticks to Their Buy Rating for CVS Health (CVS)

Allen LutzBank of America Securities

Bank of America Securities

$80→$85

Buy

33.71%

Upside

Reiterated

05/02/25

Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (NASDAQ: ADPT), CVS Health (NYSE: CVS) and Cytokinetics (NASDAQ: CYTK)

Kevin CaliendoUBS

UBS

$67→$71

Hold

11.69%

Upside

Reiterated

05/02/25

CVS Health price target raised to $71 from $67 at UBSCVS Health price target raised to $71 from $67 at UBS

Erin WrightMorgan Stanley

Morgan Stanley

$68→$80

Buy

25.85%

Upside

Reiterated

04/15/25

CVS Health price target raised to $80 from $68 at Morgan StanleyCVS Health price target raised to $80 from $68 at Morgan Stanley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CVS Health

1 Month

xxx

Success Rate

18/27 ratings generated profit

Average Return

+1.36%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +1.36% per trade.

3 Months

xxx

Success Rate

12/21 ratings generated profit

Average Return

+1.59%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +1.59% per trade.

1 Year

Michael ChernyLeerink Partners

Success Rate

16/32 ratings generated profit

Average Return

+6.70%

reiterated a buy rating 17 days ago

Copying Michael Cherny's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +6.70% per trade.

2 Years

xxx

Success Rate

14/21 ratings generated profit

Average Return

+14.81%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +14.81% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CVS Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CVS has received 29 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. CVS average Analyst price target in the past 3 months is 79.94.

Each month's total comprises the sum of three months' worth of ratings.

CVS Financial Forecast

CVS Earnings Forecast

Next quarter’s earnings estimate for CVS is $1.45 with a range of $1.32 to $1.72. The previous quarter’s EPS was $2.25. CVS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year CVS has Outperformed its overall industry.

CVS Sales Forecast

Next quarter’s sales forecast for CVS is $94.93B with a range of $90.83B to $98.80B. The previous quarter’s sales results were $94.61B. CVS beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year CVS has Outperformed its overall industry.

CVS Stock Forecast FAQ

What is CVS’s average 12-month price target, according to analysts?

Based on analyst ratings, CVS Health Corp’s 12-month average price target is 79.94.

What is CVS’s upside potential, based on the analysts’ average price target?

CVS Health Corp has 25.75% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CVS a Buy, Sell or Hold?

CVS Health Corp has a consensus rating of Strong Buy which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.

What is CVS Health Corp’s price target?

The average price target for CVS Health Corp is 79.94. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $95.00 ,the lowest forecast is $71.00. The average price target represents 25.75% Increase from the current price of $63.57.

What do analysts say about CVS Health Corp?

CVS Health Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of CVS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

CVS Health (CVS) Stock Forecast & Price Target

CVS Analyst Ratings

CVS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering CVS Health

CVS Analyst Recommendation Trends

CVS Financial Forecast

CVS Earnings Forecast

CVS Sales Forecast

CVS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts